dicyanmethane (malononitrile)

Also Known As:
malononitrile; malonitrile; malonodinitrile
Networked: 41 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results


1. Barrio, Jorge R: 16 articles (01/2013 - 01/2002)
2. Kepe, Vladimir: 15 articles (01/2013 - 01/2002)
3. Small, Gary W: 13 articles (01/2013 - 01/2002)
4. Siddarth, Prabha: 9 articles (01/2013 - 01/2002)
5. Ercoli, Linda M: 6 articles (01/2013 - 01/2002)
6. Bookheimer, Susan Y: 5 articles (01/2013 - 01/2009)
7. Lavretsky, Helen: 5 articles (01/2013 - 01/2009)
8. Miller, Karen J: 5 articles (01/2013 - 01/2009)
9. Petric, Andrej: 5 articles (03/2010 - 01/2002)
10. Satyamurthy, Nagichettiar: 5 articles (03/2010 - 01/2002)

Related Diseases

1. Alzheimer Disease (Alzheimer's Disease)
02/01/2010 - "The primary objective of this study was to develop a retrospective image-based movement correction (MC) method and evaluate its implementation on dynamic 2-(1-{6-[(2-(18)F-fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ((18)F-FDDNP) PET images of cognitively intact controls and patients with Alzheimer's disease (AD). "
01/01/2008 - "Use 2-(1-{6-[(2-[F- 18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([F-18]FDDNP) in combination with positron emission tomography (PET) to produce dynamic images for quantification of regional cortical brain deposition in MCI patients and compare them with controls subjects and patients with Alzheimer's disease (AD). "
01/01/2009 - "Positron emission tomography (PET) scans after intravenous injections of 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), which binds to plaques and tangles in vitro, demonstrate increased cerebral binding in patients with Alzheimer disease compared with cognitively intact controls. "
04/01/2009 - "The distinctive cortical uptake of the tracer (18)F-FDDNP (2-(1-{6-[(2-fluoroethyl(methyl)amino]-2-naphthyl}ethylidene)malononitrile) in Alzheimer's disease (AD) is believed to be because of its binding to both neurofibrillary tangles (NFTs) and highly fibrillar senile plaques. "
11/01/2006 - "2-(1-{6-[(2-[F-18]Fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([F-18]FDDNP) positron emission tomography also shows a pattern of neuropathology distribution for frontotemporal dementia that differs from that of Alzheimer's disease. "
2. Kuru
3. Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease)
4. Amyloid Plaque
07/01/2012 - "Positron emission tomography (PET) scans using 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP) can measure levels of amyloid plaques and tau neurofibrillary tangles in vivo. "
04/01/2009 - "The distinctive cortical uptake of the tracer (18)F-FDDNP (2-(1-{6-[(2-fluoroethyl(methyl)amino]-2-naphthyl}ethylidene)malononitrile) in Alzheimer's disease (AD) is believed to be because of its binding to both neurofibrillary tangles (NFTs) and highly fibrillar senile plaques. "
06/01/2009 - "To address this issue, the authors obtained positron emission tomography (PET) scans after intravenous injections of 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), a molecule that binds to amyloid plaques and neurofibrillary tangles, to determine whether symptoms of depression and anxiety in nondemented subjects were associated with increased FDDNP-PET binding values. "
08/15/2010 - "Here, we show that positron emission tomography (PET) imaging using the three radiotracers (11)C-Pittsburgh compound B (PIB), 2-(1-{6-[(2-(18)F-fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile (FDDNP), and 2-[18F]fluoro-2-deoxy-d-glucose (FDG), in the same subjects, with and without AD, can provide valuable information on the pathological patterns of the distribution of tracers for amyloid plaque, neurofibrillary tangle, and glucose hypometabolism in AD. "
01/01/2002 - "The authors used 2-(1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile ([18F]FDDNP), a hydrophobic radiofluorinated derivative of 2-(1-[6-(dimethylamino)-2-naphthyl]ethylidene)malononitrile (DDNP), in conjunction with positron emission tomography to determine the localization and load of neurofibrillary tangles (NFTs) and beta-amyloid senile plaques (APs) in the brains of living Alzheimer disease (AD) patients. "
5. Carcinoma (Carcinomatosis)

Related Drugs and Biologics

1. Paraffin
2. 2- (1- (6- ((2- fluoroethyl)(methyl)amino)- 2- naphthyl)ethylidene)malononitrile
3. Amyloid (Amyloid Fibrils)
4. o-Chlorobenzylidenemalonitrile (Tear Gas, CS)
5. Fluorine
6. Protein-Tyrosine Kinases (Tyrosine Kinase)
7. Glucose (Dextrose)
8. Platelet-Derived Growth Factor alpha Receptor
9. Tyrphostins
10. Zymosan

Related Therapies and Procedures

1. Intravenous Injections
2. Ligation
3. Spinal Injections